Skip to main content
. Author manuscript; available in PMC: 2021 Mar 31.
Published in final edited form as: FASEB J. 2020 Aug 11;34(10):13533–13547. doi: 10.1096/fj.201903292RR

Figure 4. Hepatic E4bp4 is required for tunicamycin-induced accumulation of lipid droplets in PMHs.

Figure 4.

(A) Validation of liver-specific E4bp4 deficiency in various tissues isolated from both E4bp4flox/flox (n=3) and E4bp4-LKO (n=3) mice by RT-qPCR. PMHs were isolated from E4bp4flox/flox and E4bp4-LKO mice and treated with tunicamycin overnight prior to BODIPY staining for lipid droplets and RNA extraction for RT-qPCR. (B) Image of lipid droplet formation after tunicamycin treatment; lipid droplets in 50 cells were countered per condition and presented in the bar graph; (C) Cellular triglycerides (TG) content in tunicamycin-treated E4bp4flox/flox or E4bp4-LKO PMHs; (D) Lipid metabolic genes assessed in PMHs of E4bp4-LKO mice following tunicamycin treatment.